China Biopharma Giant's Major Acquisition Sparks Broad Rally in Hong Kong Healthcare Stocks

Deep News01-14

On the morning of January 14th, the Hang Seng Healthcare ETF (159892) and the Hong Kong Stock Connect Healthcare ETF (520510) surged by more than 3% at one point. AliHealth jumped over 11%, with MicroPort Robot, Zai Lab, and MicroPort Medical leading the gains strongly. SINO BIOPHARM, BeiGene, and others also followed the upward trend. On the news front, SINO BIOPHARM issued an announcement declaring its intention to fully acquire the domestic siRNA innovator drug company, Hejiya Biotech, for a total consideration of 1.2 billion RMB. This marks another significant strategic move by the company in the small nucleic acid therapeutics field, following its previous investment in Shenggen Biotech. Furthermore, BeiGene announced today that its self-developed Class I new drug, Baiyueda, a novel BCL2 inhibitor, has commenced distribution starting January 13th, with the initial batch of the drug covering 70 cities across the country.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1137484597?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-14 12:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1137484597","market":"other","top_or_hot":-1,"title":"China Biopharma Giant's Major Acquisition Sparks Broad Rally in Hong Kong Healthcare Stocks","media":"Deep News","content":"<p>On the morning of January 14th, the Hang Seng Healthcare ETF (159892) and the Hong Kong Stock Connect Healthcare ETF (520510) surged by more than 3% at one point. AliHealth jumped over 11%, with MicroPort Robot, Zai Lab, and MicroPort Medical leading the gains strongly. SINO BIOPHARM, BeiGene, and others also followed the upward trend. On the news front, SINO BIOPHARM issued an announcement declaring its intention to fully acquire the domestic siRNA innovator drug company, Hejiya Biotech, for a total consideration of 1.2 billion RMB. This marks another significant strategic move by the company in the small nucleic acid therapeutics field, following its previous investment in Shenggen Biotech. Furthermore, BeiGene announced today that its self-developed Class I new drug, Baiyueda, a novel BCL2 inhibitor, has commenced distribution starting January 13th, with the initial batch of the drug covering 70 cities across the country.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China Biopharma Giant's Major Acquisition Sparks Broad Rally in Hong Kong Healthcare Stocks</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina Biopharma Giant's Major Acquisition Sparks Broad Rally in Hong Kong Healthcare Stocks\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-01-14 12:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>On the morning of January 14th, the Hang Seng Healthcare ETF (159892) and the Hong Kong Stock Connect Healthcare ETF (520510) surged by more than 3% at one point. AliHealth jumped over 11%, with MicroPort Robot, Zai Lab, and MicroPort Medical leading the gains strongly. SINO BIOPHARM, BeiGene, and others also followed the upward trend. On the news front, SINO BIOPHARM issued an announcement declaring its intention to fully acquire the domestic siRNA innovator drug company, Hejiya Biotech, for a total consideration of 1.2 billion RMB. This marks another significant strategic move by the company in the small nucleic acid therapeutics field, following its previous investment in Shenggen Biotech. Furthermore, BeiGene announced today that its self-developed Class I new drug, Baiyueda, a novel BCL2 inhibitor, has commenced distribution starting January 13th, with the initial batch of the drug covering 70 cities across the country.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1521","symbol_name":"挪威政府全球养老基金持仓","start_time":0,"source_url":"","article_id":"1137484597","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1137484597","pubTimestamp":1768363407,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"On the morning of January 14th, the Hang Seng Healthcare ETF (159892) and the Hong Kong Stock Connect Healthcare ETF (520510) surged by more than 3% at one point. AliHealth jumped over 11%, with...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159718":"港股医药","BK1521":"挪威政府全球养老基金持仓","BK1515":"抗疫概念","BK1191":"制药","IE00BZ08YT58.USD":"GUINNESS BEST OF CHINA \"C\" (USD) ACC","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","01177":"中国生物制药","IE00BZ08YS42.EUR":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC","IE00BZ08YR35.GBP":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","BK1589":"北水核心资产"},"translate_title":"中国生物制药巨头重大收购引发香港医疗保健股广泛上涨","themeId":"19a45d98d676f675f3dd1dad1f11fa69","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159718":1,"01177":1},"content_text":"On the morning of January 14th, the Hang Seng Healthcare ETF (159892) and the Hong Kong Stock Connect Healthcare ETF (520510) surged by more than 3% at one point. AliHealth jumped over 11%, with MicroPort Robot, Zai Lab, and MicroPort Medical leading the gains strongly. SINO BIOPHARM, BeiGene, and others also followed the upward trend. On the news front, SINO BIOPHARM issued an announcement declaring its intention to fully acquire the domestic siRNA innovator drug company, Hejiya Biotech, for a total consideration of 1.2 billion RMB. This marks another significant strategic move by the company in the small nucleic acid therapeutics field, following its previous investment in Shenggen Biotech. Furthermore, BeiGene announced today that its self-developed Class I new drug, Baiyueda, a novel BCL2 inhibitor, has commenced distribution starting January 13th, with the initial batch of the drug covering 70 cities across the country.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1137484597","isCrawlerRequest":true}